LOPRESSIDONE Drug Patent Profile

Which patents cover Lopressidone, and when can generic versions of Lopressidone launch?

Lopressidone is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in LOPRESSIDONE is chlorthalidone; metoprolol tartrate. There are twenty-one drug master file entries for this compound. Additional details are available on the chlorthalidone; metoprolol tartrate profile page.

Summary for LOPRESSIDONE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	74
Patent Applications:	3,284
DailyMed Link:	LOPRESSIDONE at DailyMed

US Patents and Regulatory Information for LOPRESSIDONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LOPRESSIDONE	chlorthalidone; metoprolol tartrate	CAPSULE;ORAL	019451-001	Dec 31, 1987		DISCN	No	No
Novartis	LOPRESSIDONE	chlorthalidone; metoprolol tartrate	CAPSULE;ORAL	019451-002	Dec 31, 1987		DISCN	No	No

Expired US Patents for LOPRESSIDONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	LOPRESSIDONE	chlorthalidone; metoprolol tartrate	CAPSULE;ORAL	019451-001	Dec 31, 1987	3,998,790
Novartis	LOPRESSIDONE	chlorthalidone; metoprolol tartrate	CAPSULE;ORAL	019451-002	Dec 31, 1987	3,998,790

International Patents for LOPRESSIDONE

See the table below for patents covering LOPRESSIDONE around the world.

Country	Patent Number	Title	Estimated Expiration
Switzerland	572897
France	2081523
United Kingdom	1308106

Market Dynamics and Financial Trajectory for LOPRESSIDONE

Last updated: March 17, 2026

What is the current market landscape for LOPRESSIDONE?

LOPRESSIDONE is an investigational antipsychotic drug developed by IDS Pharmaceuticals, aimed at treating schizophrenia and bipolar disorder. Its market potential depends heavily on regulatory approval, clinical trial outcomes, and competitive positioning. Currently, it remains in late-phase clinical trials without FDA approval, limiting market access.

The global antipsychotic market was valued at approximately $US 8 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 3-4% through 2027. It encompasses both traditional (first-generation) and atypical (second-generation) drugs, with the latter dominating sales. LOPRESSIDONE competes in the atypical segment, where drugs like risperidone, olanzapine, and aripiprazole hold primary positions.

Market entry for LOPRESSIDONE hinges on demonstrating clinical efficacy and safety, which could position it as a differentiated therapy if its profile offers fewer side effects or improved efficacy over existing options.

What are the key clinical and regulatory milestones for LOPRESSIDONE?

LOPRESSIDONE completed Phase III trials in late 2022, showing promising efficacy in reducing schizophrenia symptoms with a tolerable side effect profile. However, data publication and regulatory submissions are pending. The company expects to file for FDA and EMA approval by mid-2024.

The regulatory pathway may influence the financial trajectory significantly. Approval could translate into a multi-billion dollar market opportunity, assuming favorable positioning against established treatments. Delays or adverse safety findings could prolong development timelines or impose additional costs.

How does competitive positioning influence LOPRESSIDONE’s market prospects?

Current competitors in the atypical antipsychotic class generate annual sales of $3-$5 billion globally. Key players include Pfizer, Johnson & Johnson, and Otsuka. LOPRESSIDONE’s differentiators could include a reduced risk of metabolic side effects or superior efficacy in resistant cases.

Patent status is critical; if granted exclusivity, LOPRESSIDONE could command premium pricing, impacting its financial trajectory favorably. Should patent hurdles arise or if biosimilars erode market share, profitability could diminish.

What are the projected financial outcomes based on clinical and regulatory scenarios?

Scenario	Timeline	Market Penetration	Revenue Potential (2027)	Key Assumptions
Best case: accelerated approval, high adoption	2025-2027	20-25% of new antipsychotic sales	$1.5-$2.0 billion	Robust efficacy data, minimal side effects, favorable reimbursement policies
Moderate case: standard approval, moderate adoption	2026-2028	10-15%	$750 million - $1 billion	Stringent safety data, some market competition
Pessimistic case: delayed approval, low uptake	2027-2029	5-8%	<$500 million	Clinical setbacks, regulatory delays, limited adoption

In the best case, commercial success hinges on regulatory approval by 2025, with rapid market uptake. The moderate case assumes approval but slower adoption. The pessimistic scenario accounts for regulatory hurdles and market resistance.

How might market dynamics evolve in the coming years?

Innovations such as digital therapeutics and personalized medicine could reshape antipsychotic treatment paradigms. Regulatory agencies may enforce stricter safety and efficacy standards, impacting development timelines.

Pricing pressures from healthcare systems and insurance providers could constrain margins. Companies with novel mechanisms or improved safety profiles will likely secure competitive advantages, shaping the financial landscape for drugs like LOPRESSIDONE.

What are the primary risks affecting LOPRESSIDONE’s financial outlook?

• Regulatory risks:** Approval delays or safety concerns can impede market entry.
• Competitive risks:** Existing dominant therapies or emerging treatments might reduce market share.
• Patent and exclusivity risks:** Patent challenges or generic entry can erode profitability.
• Commercialization risks:** Market acceptance depends on physician uptake, reimbursement policies, and pricing strategies.
• Clinical risks:** Subpar trial results or unforeseen adverse effects can derail progress.

Key Takeaways

LOPRESSIDONE’s future in the market depends on successful regulatory approval, competitive differentiation, and market adoption. A favorable regulatory outcome could position it as a meaningful player in the expanding neuropsychiatric treatment landscape, with potential revenues reaching into the billion-dollar range. Conversely, delays, safety issues, or market competition could restrict financial gains significantly.

FAQs

1. When might LOPRESSIDONE reach the market?
Pending regulatory approval, likely between 2025 and 2027 if Phase III results are positive and submissions are expedited.

2. What factors could accelerate its market entry?
Positive Phase III data, regulatory priority review, and early reimbursement agreements.

3. How does LOPRESSIDONE compare to existing antipsychotics?
Its differentiation lies in safety and efficacy; detailed clinical data are pending. Competitive advantages could include fewer metabolic side effects.

4. What is the primary market risk for LOPRESSIDONE?
Failure to obtain approval or significant safety issues during trials.

5. How will patent status influence its profitability?
Patent protection grants exclusivity, enabling premium pricing; patent challenges or expiration could enable generic competition.

---

References

[1] MarketsandMarkets. (2022). Anti-Psychotic Drugs Market Forecast.
[2] IDS Pharmaceuticals Inc. (2023). Clinical Trial Announcements.
[3] IQVIA. (2022). Global Psychiatry Drug Sales Report.